🎙 Listen to a summary of this story
China’s ability to move promising drugs into early clinical trials quickly and at relatively low cost has helped make its biotechnology companies attractive partners for global pharmaceutical groups. Now, growing scrutiny in Washington is raising a question for those partnerships: Will evidence gathered in China be enough to carry a drug through development and into the U.S. market?
U.S. lawmakers and Food and Drug Administration officials have expressed concern about American drugmakers’ reliance on early trials in China, citing questions about transparency and the desire to retain medical innovation in the United States, according to the South China Morning Post. The prospect of closer examination could make companies more cautious when licensing drugs whose first human studies were conducted there. :chatgpt-content-reference{index="0"}
That does not mean Chinese trial results are automatically unreliable or that U.S. regulators have barred their use. The FDA has long accepted qualifying studies conducted abroad. The issue is whether a particular trial protects participants, produces dependable results and answers questions relevant to patients who may receive the drug elsewhere.
Speed meets a global test
China offers drug developers a large patient population, experienced research hospitals and a growing biotechnology industry. Those strengths can help companies recruit participants and identify promising treatments, particularly in cancer research. For a small biotech company, encouraging early results may also attract the funding or pharmaceutical partner needed to run a larger study.
But an early trial and an approval application serve different purposes. A study can show that a drug is worth investigating without establishing that it works for a broader population. Differences in medical practice, available treatments and the patients enrolled may affect how regulators interpret its findings.
FDA oncology officials have pointed to the increasing number of trials conducted exclusively in China or enrolling a substantial share of participants there. In a 2025 discussion of global cancer research, the agency said it had limited experience with some Chinese trial sites. It favored genuinely multiregional studies, which would allow reviewers to compare results from China with those from the United States and other locations. :chatgpt-content-reference{index="1"}
The concern extends beyond checking whether investigators recorded data correctly. Regulators must also judge whether a study’s results apply to the people and health care systems where a drug would be used. That can be difficult when most participants come from one country, even if the study was conducted carefully.
What regulators require
FDA rules allow foreign clinical studies conducted outside its investigational new drug system to support U.S. drug applications if they meet good clinical practice standards. Those standards cover both the integrity of the evidence and the treatment of participants, including independent ethics review and informed consent. They have been part of the agency’s rules since 2008, rather than a new requirement aimed specifically at China. :chatgpt-content-reference{index="2"}
For developers, that places a premium on records that can be examined and explained: how patients were selected, whether sites followed the study plan, how outcomes were measured and how possible side effects were reported. If a company intends to seek approval in several countries, it also has to plan early for the evidence each regulator will need.
European requirements add another consideration. The European Medicines Agency says trials submitted in support of an EU marketing application must meet applicable ethical and good clinical practice principles regardless of where they took place. A fast study in China may therefore offer a commercial head start, but its value to an international partner depends on whether the results can withstand review abroad. :chatgpt-content-reference{index="3"}
Washington’s concerns also include a distinct issue: the handling of Americans’ biological material. In June 2025, the FDA announced a review of new trials involving U.S. patients’ living cells being sent to China and other countries for genetic engineering before being returned for treatment. The agency cited questions about consent and sensitive genetic information. That action concerns a specific type of cross-border trial; it is not a general prohibition on clinical research in China. :chatgpt-content-reference{index="4"}
The cost of proving results
For Chinese biotechs, the practical response may be to design international development plans sooner. A company hoping to sell or license a drug globally could include sites outside China in later studies, seek early advice from regulators and budget for the oversight needed to make results credible across markets.
Those steps cost money and can take time. They may narrow the speed and cost advantage that made Chinese research attractive in the first place. Yet they could also increase the value of a successful drug by giving prospective partners greater confidence in the evidence behind it.
Multinational pharmaceutical companies face the same calculation. Passing over promising Chinese discoveries could mean missing useful treatments. Committing to a drug before understanding its clinical record could leave them paying for additional studies, delaying an application or discovering that early findings do not hold up in a larger trial.
China’s research capacity remains a major asset. The outcome will be decided study by study: by the quality of the evidence, the protections afforded to participants and whether results can be shown to apply beyond the hospitals where they were first gathered. As scrutiny rises, the most valuable advantage may be the ability to produce findings that regulators and patients in multiple countries can trust.
